TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$5.64 +0.02 (+0.36%) (As of 09/6/2024 ET) Add Compare Share Share Today's RangeC$5.60▼C$5.6550-Day RangeC$5.48▼C$5.8652-Week RangeC$4.35▼C$6.22Volume45,301 shsAverage Volume63,616 shsMarket CapitalizationC$570.82 millionP/E RatioN/ADividend YieldN/APrice TargetC$7.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Knight Therapeutics alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Knight Therapeutics Stock (TSE:GUD)Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Stock News HeadlinesAugust 21, 2024 | insidertrades.comAmal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockAugust 12, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc. (GUD.TO)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 8, 2024 | markets.businessinsider.comKnight Therapeutics earnings: here's what to expectJuly 24, 2024 | finance.yahoo.comKnight Therapeutics Inc. (KHTRF)May 15, 2024 | seekingalpha.comGUD:CA Knight Therapeutics Inc.May 12, 2024 | seekingalpha.comKnight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call TranscriptApril 21, 2024 | investing.comKnight Therapeutics Inc (GUD)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.April 16, 2024 | msn.comTSX Healthcare in April 2024: The Best Stocks to Buy Right NowApril 9, 2024 | finance.yahoo.comKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 23, 2024 | investing.comEarnings call: Knight Therapeutics announced record revenues of $343 millionMarch 22, 2024 | finance.yahoo.comKnight Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 20, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc (04K.SG)March 14, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.March 7, 2024 | finance.yahoo.comFavourable Signals For Knight Therapeutics: Numerous Insiders Acquired StockFebruary 29, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.,February 29, 2024 | msn.comKnight Therapeutics launches Minjuvi in BrazilSee More Headlines Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Stock Price TargetC$7.08 High Stock Price TargetC$7.50 Low Stock Price TargetC$6.75 Potential Upside/Downside+25.6%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.20) Trailing P/E RatioN/A Forward P/E Ratio196.14 P/E Growth-1013.5Net IncomeC$-21,230,000.00 Net Margins-6.28% Pretax MarginN/A Return on Equity-2.70% Return on Assets0.51% Debt Debt-to-Equity Ratio7.62 Current Ratio3.41 Quick Ratio1.79 Sales & Book Value Annual SalesC$337.87 million Price / Sales1.69 Cash FlowC$1.47 per share Price / Cash Flow3.85 Book ValueC$7.53 per share Price / Book0.75Miscellaneous Outstanding Shares101,210,000Free FloatN/AMarket CapC$570.82 million OptionableNot Optionable Beta0.48 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Comp: $250.94kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Comp: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human ResourcesMore ExecutivesKey CompetitorsTilray BrandsTSE:TLRYCronos GroupTSE:CRONHydropothecaryCVE:THCXCanopy GrowthTSE:WEEDCipher PharmaceuticalsTSE:CPHView All CompetitorsInsidersAmal KhouriSold 5,000 sharesTotal: C$28,919.00 ($5.78/share)Amal KhouriSold 500 sharesTotal: C$2,875.00 ($5.75/share)Amal KhouriSold 5,000 sharesTotal: C$28,750.00 ($5.75/share)Amal KhouriSold 10,000 sharesTotal: C$57,000.00 ($5.70/share)Amal KhouriSold 10,000 sharesTotal: C$57,200.00 ($5.72/share)View All Insider Transactions GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$5.19 on January 1st, 2024. Since then, GUD stock has increased by 8.7% and is now trading at C$5.64. View the best growth stocks for 2024 here. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) announced its earnings results on Thursday, August, 8th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.05. The company had revenue of $95.57 million for the quarter, compared to analysts' expectations of $89.83 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 2.70% and a negative net margin of 6.28%. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B) and Chemtrade Logistics Income Fund (CHE.UN). This page (TSE:GUD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GUD Stock Alerts